Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) EBITDA Margin (2020 - 2022)

Immuneering (IMRX) has 3 years of EBITDA Margin data on record, last reported at 2886419.34% in Q4 2022.

  • For Q4 2022, EBITDA Margin fell 288070777.0% year-over-year to 2886419.34%; the TTM value through Sep 2023 reached 11315518.9%, down 1130599682.0%, while the annual FY2022 figure was 15931.33%, 1431665.0% down from the prior year.
  • EBITDA Margin reached 2886419.34% in Q4 2022 per IMRX's latest filing, down from 33364.36% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 644.66% in Q3 2020 and bottomed at 2886419.34% in Q4 2022.
  • Average EBITDA Margin over 3 years is 295013.98%, with a median of 3741.31% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: crashed -112641bps in 2021, then plummeted -288070777bps in 2022.
  • A 3-year view of EBITDA Margin shows it stood at 877.48% in 2020, then tumbled by -551bps to 5711.57% in 2021, then plummeted by -50436bps to 2886419.34% in 2022.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 2886419.34% in Q4 2022, 33364.36% in Q3 2022, and 12223.67% in Q2 2022.